GSK Trims Nutritional Drink Lines, Wants All Of Its Consumer JV Pie
This article was originally published in The Pink Sheet
Executive Summary
With its July 26 earnings report, the UK firm made clear it's ready to become sole owner of its consumer health JV with Novartis, and that divesting UK brands Horlicks and MaxiNutrition are among its steps toward cutting manufacturing costs.
You may also be interested in...
Consumer Business Reliable And Right At Home At GlaxoSmithKline
CEO Walmsley's familiarity with Glaxo's consumer health business was clear in her response to analysts' questions about the firm's future as a three-unit operation. The business marketing brands including Flonase and Excedrin is a more reliable revenue driver than the pharma business, she said.
Glaxo In Charge, And The World Is GSK/Novartis Consumer Product JV’s Oyster
GSK Consumer Healthcare not only is the name of Glaxo/Novartis JV, but also the brand being added to Novartis’ OTC products. The JV will access OTC switch opportunities across the Rx portfolios of both Glaxo and Novartis in addition to external partners, says Americas/Europe head Brian McNamara.
‘Recipe For Disaster’ In Supplement Manufacturing? US DoJ Attorney Cooks Up Likely Causes
"You end up with a recipe for maybe there's adulterants in the product. Maybe the product wasn't manufactured according to the spec, so it's misbranded. Worse, there could be adulterants. In some of those ingredients, there's a lot of potential failures,” says Patrick Runkle, senior litigation counsel at DoJ Consumer Protection Branch, during FDL conference.